Actinium Pharmaceuticals (ATNM) Shares Up 4.1%
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares shot up 4.1% on Tuesday . The stock traded as high as $0.77 and last traded at $0.76. 1,230,300 shares traded hands during trading, an increase of 8% from the average session volume of 1,142,880 shares. The stock had previously closed at $0.73.
A number of analysts have commented on ATNM shares. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. B. Riley upped their target price on shares of Actinium Pharmaceuticals from $2.75 to $3.00 and gave the company a “buy” rating in a report on Thursday, July 12th. Finally, Maxim Group reaffirmed a “buy” rating and set a $3.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, August 14th. Five investment analysts have rated the stock with a buy rating, Actinium Pharmaceuticals has a consensus rating of “Buy” and an average price target of $3.75.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.02.
Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Featured Story: Market Capitalization in the Stock Market
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.